This document outlines details of PBS-subsidised azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings, Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS), and Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Acute myeloid leukaemia (AML) quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial
|
Telephone
Electronic
S100:
azacitidine injection
S85:
decitabine+cedazuridine (general listing)
|
No |
OPA |
Not specified |
Yes |
|
Continuing
|
Streamlined
S100:
azacitidine injection
S85:
decitabine+cedazuridine (general listing)
|
No |
N/A |
Not specified
|
N/A |
|
Induction consolidation
|
Telephone
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Initial maintenance
PB253 form |
Written
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Continuing
maintenance
|
Telephone
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Initial treatment
following intensive induction chemotherapy
|
Telephone
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Continuing treatment
following intensive induction chemotherapy
|
Telephone
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Continuing treatment
Dose escalation therapy
PB355 form
|
Written
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Induction |
Telephone
Electronic
S100 EFC:
daunorubicin+cytarabine |
No |
OPA |
Not specified |
Yes |
|
Consolidation |
Telephone
Electronic
S100 EFC:
daunorubicin+cytarabine |
No |
OPA |
Not specified |
Yes |
Expand all